Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: hirasawa y. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559573 Free PMC article.
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Onoue R, Kubota Y, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. Ando K, et al. Among authors: hirasawa y. Anticancer Res. 2019 Sep;39(9):5195-5201. doi: 10.21873/anticanres.13716. Anticancer Res. 2019. PMID: 31519633
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
Ohkuma R, Yada E, Ishikawa S, Komura D, Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, Ariizumi H, Satoh E, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Yokobori T, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Izumizaki M, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: hirasawa y. PLoS One. 2020 Jan 10;15(1):e0226707. doi: 10.1371/journal.pone.0226707. eCollection 2020. PLoS One. 2020. PMID: 31923206 Free PMC article.
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI. Matsumoto N, et al. Among authors: hirasawa y. Cancer Chemother Pharmacol. 2020 Jun;85(6):1119-1128. doi: 10.1007/s00280-020-04087-z. Epub 2020 May 26. Cancer Chemother Pharmacol. 2020. PMID: 32458030
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer.
Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: hirasawa y. Oncol Rep. 2020 Jul;44(1):252-262. doi: 10.3892/or.2020.7610. Epub 2020 May 11. Oncol Rep. 2020. PMID: 32627041 Free PMC article.
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.
Ando K, Hamada K, Shida M, Ohkuma R, Kubota Y, Horiike A, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. Ando K, et al. Among authors: hirasawa y. Cancer Immunol Immunother. 2021 Feb;70(2):337-348. doi: 10.1007/s00262-020-02686-6. Epub 2020 Aug 5. Cancer Immunol Immunother. 2021. PMID: 32757055 Free PMC article.
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer.
Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: hirasawa y. Int J Oncol. 2021 Jan;58(1):57-69. doi: 10.3892/ijo.2020.5147. Epub 2020 Nov 12. Int J Oncol. 2021. PMID: 33367933 Free PMC article.
The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer.
Ohkuma R, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Aoki T, Murakami M, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: hirasawa y. Pancreas. 2021 Feb 1;50(2):167-175. doi: 10.1097/MPA.0000000000001731. Pancreas. 2021. PMID: 33565793
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer.
Kubota Y, Yoshimura K, Hamada K, Hirasawa Y, Shida M, Taniguchi M, Matsui H, Ariizumi H, Ishiguro T, Suzuki N, Ohkuma R, Sambe T, Ishida H, Horiike A, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Kobayashi S, Tsunoda T. Kubota Y, et al. Among authors: hirasawa y. In Vivo. 2021 May-Jun;35(3):1865-1875. doi: 10.21873/invivo.12449. In Vivo. 2021. PMID: 33910874 Free PMC article.
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y, Yoshimura K, Matsui H, Kubota Y, Ishida H, Arai J, Sakaki M, Oguro N, Shida M, Taniguchi M, Hamada K, Ariizumi H, Ishiguro T, Ohkuma R, Sambe T, Horiike A, Imamura CK, Shiozawa E, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Tate G, Kobayashi S, Tsunoda T. Hirasawa Y, et al. Medicine (Baltimore). 2021 Jun 11;100(23):e25774. doi: 10.1097/MD.0000000000025774. Medicine (Baltimore). 2021. PMID: 34114983 Free PMC article.
673 results